We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    Promentis | Recruiting, Not yet recruiting Studies
Previous Study | Return to List | Next Study

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers

This study is currently recruiting participants.
Verified September 2017 by Promentis Pharmaceuticals, Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT03301298
First Posted: October 4, 2017
Last Update Posted: October 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Celerion
Information provided by (Responsible Party):
Promentis Pharmaceuticals, Inc.
  Purpose
This is a randomized, double-blind, placebo-controlled, single ascending oral dose and food effect study conducted at one study center in the United States. Safety and tolerability will be assessed throughout the study and serial blood samples and urine samples will be collected for the safety and pharmacokinetic assessment of SXC-2023.

Condition Intervention Phase
Healthy Drug: SXC-2023 or Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Food Effect of SXC-2023 When Administered Orally to Healthy Adult Subjects

Further study details as provided by Promentis Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Treatment related adverse events [ Time Frame: 8 days ]
    Treatment related adverse events as a measure of safety and tolerability of SXC-2023


Secondary Outcome Measures:
  • Pharmacokinetic Assessments: Cmax [ Time Frame: 72 hours ]
    Peak plasma concentration

  • Pharmacokinetics Assessments: Tmax [ Time Frame: 72 hours ]
    Time to peak plasma concentration

  • Pharmacokinetic Assessments: AUC [ Time Frame: 72 hours ]
    Area under the plasma concentration-time curve

  • Pharmacokinetic: Food effect, AUC [ Time Frame: 72 hours ]
    To evaluate the effect of food on the PK of SXC-2023. The log transformed values of total AUC will be analyzed using a linear mixed effect model with formulation, period, sequence, and carryover as fixed effects and subject as a random effect.

  • Pharmacokinetic: Food effect, CMax [ Time Frame: 72 hours ]
    To evaluate the effect of food on the PK of SXC-2023. The log transformed values of total CMax will be analyzed using a linear mixed effect model with formulation, period, sequence, and carryover as fixed effects and subject as a random effect.


Estimated Enrollment: 40
Actual Study Start Date: September 11, 2017
Estimated Study Completion Date: February 2018
Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SXC-2023
Dose escalation
Drug: SXC-2023 or Placebo
Oral capsule
Placebo Comparator: Placebo
Dose escalation
Drug: SXC-2023 or Placebo
Oral capsule

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy adult male or females (women of non child bearing potential), 18-55 years of age (inclusive).
  2. Medically healthy with no clinically significant screening results.
  3. Non-vasectomized male subjects must agree to use birth control or abstain from sexual intercourse during and until 90 days beyond the last dose of study drug/placebo.
  4. Continuous non-smoker, at least 3 months prior to first dose and throughout the study.
  5. Understands the study procedures in the informed consent form, and be willing and able to comply with the protocol

Exclusion Criteria:

  1. Subject is mentally or legally incapacitated.
  2. History of any illness that, in the opinion of the PI, might confound the results of the study or poses an additional risk to the subjects by their participation in the study.
  3. History or presence of alcoholism or drug abuse within the past 2 years
  4. Female subject of childbearing potential.
  5. Blood donation or significant blood loss within 56 days prior to first dose.
  6. Plasma donation within 7 days prior to first dose.
  7. Participation in another clinical trial within 30 days prior to first dose.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03301298


Contacts
Contact: Celerion Participant Registration 1-866-445-7033 info@celerion.com

Locations
United States, Arizona
Celerion Recruiting
Tempe, Arizona, United States, 85283
Contact: Dr. O'Reilly         
Principal Investigator: O'Reilly, MD         
Sponsors and Collaborators
Promentis Pharmaceuticals, Inc.
Celerion
Investigators
Study Director: Tricia Cotter Promentis Pharmaceuticals, Inc.
  More Information

Responsible Party: Promentis Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03301298     History of Changes
Other Study ID Numbers: PRO-101
First Submitted: September 26, 2017
First Posted: October 4, 2017
Last Update Posted: October 23, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No